AARP Analysis Highlights Substantial Cost Savings for Nearly Nine Million
Medicare Part D Enrollees





 



DOSE OF REALITY: NEW REPORT PROJECTS MORE THAN 50 PERCENT DROP IN
OUT-OF-POCKET COSTS FOR TOP MEDICARE DRUGS IN 2026

AARP Analysis Highlights Substantial Cost Savings for Nearly Nine Million
Medicare Part D Enrollees



A new analysis
<[link removed]>
released by AARP finds out-of-pocket expenses for 10 high-cost prescription
drugs are projected to fall by an average of more than 50 percent for Medicare
Part D enrollees when lower prices take effect on January 1, 2026. The
analysis, conducted in December 2025, “examined enrollee cost-sharing and other
coverage characteristics among stand-alone Part D plans that were available in
five states with high Medicare enrollment.”



The analysis found that substantial reductions in enrollee cost-sharing will
lead to lower monthly out-of-pocket costs for patients, including expected
reductions of more than 50 percent on seven of the 10 drugs analyzed. The
report notes that this “will greatly reduce enrollees’ out-of-pocket costs in
2026, likely due to the prevalence of cost-sharing that is directly linked to
drug prices.”



Average Monthly Enrollee Costs For Top Medicare Drugs: 2025 vs. 2026



AARP’s analysis also found that seven of the 10 drugs are set to cost less
than $100 per month – up from only two drugs in 2025 – once new policies to
lower drug prices take effect. While three drugs – Amgen’s rheumatoid arthritis
drug Enbrel, Johnson & Johnson and AbbVie’s cancer drug Imbruvica and Johnson &
Johnson’s psoriasis drug Stelara – will still have comparatively higher price
tags, Medicare Part D beneficiaries will benefit from a new out-of-pocket
spending cap of $2,100 in 2026. Additionally, all stand-alone Part D plans
included in the study will cover each drug in 2026, representing an increase
from current coverage levels.



As highlighted in the analysis, the Centers for Medicare and Medicaid Services
(CMS) noted these policies “could save enrollees a collective $1.5 billion in
out-of-pocket expenses in 2026.”



While these findings represent positive progress toward lowering prescription
drug prices for Americans struggling to afford their medications, lawmakers
must continue to work in a bipartisan fashion to advance market-based solutions
that hold Big Pharma accountable.



Read the full Report from AARP HERE
<[link removed]>
.



Read more about Big Pharma’s egregious pricing practices and
direct-to-consumer advertising on these 10 drugsHERE
<[link removed]>
.



Read more on bipartisan, market-based solutions to hold Big Pharma accountable
HERE <[link removed]>.

































Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx


This email was sent to [email protected]. To unsubscribe please click
here.
<[link removed]>